Individuals that have been injured by a defective medication need experienced attorneys on their side. Contact our office today for qualified legal guidance.

DRUG AND MEDICAL DEVICE LITIGATION

Our firm has represented clients in class action suits against the manufacturers of such injury-causing drugs as Rezulin®, Propulsid®, and Fen-Phen. Today, drug manufacturers Pfizer, Inc. and Merck & Company may be held liable for marketing potentially dangerous products. Attorney H. Lee Thompson is currently accepting new clients from across the nation who have sustained permanent injuries as a result of using these dangerous drugs. Contact our office today for a free consultation.

Trasylol®

On September 21, 2006 an FDA advisory committee, after reviewing extensive data at a public meeting, concluded that Trayslol was still acceptably safe and effective for certain patients.

Bayer AG, the pharmaceutical manufacturer, has marketed this drug injection since 1993. Some days after the advisory meeting a whistleblower, possibly an outside medical researcher, reportedly called the FDA. Bayer had been forced to make a full disclosure. Results of a study by Bayer not disclosed to the committee showed that Trayslol/Aprotinin may increase the chance for death, serious kidney disease, congestive heart failure, and strokes in heart surgery patients.

Trasylol/Aprotinin has been used in heart surgery to reduce blood loss and the need for transfusion since 1993. Two studies published this year again found that Trasylol increased the risk of kidney failure, heart attack, and stroke. The Ischemia Research and Education Foundation published its research in the New England Journal of Medicine in 2008. The results were that following hear surgery a patient had an increased risk of kidney failure by more than 2 ½ times (250%). CBS’ 60 Minutes provided a special investigation on February 17, 2008, of a report of a patient and family that have sued Bayer Corporation because the patient died.

If you or someone you know underwent open heart surgery and had kidney problems (with or without dialysis) soon afterward, usually during the hospitalization resulting from the heart surgery, please contact The Thompson Law Firm today for a free consultation.

Gadolinium

Gadolinium based contrast agents are often used to enhance the quality of MRI’s. However, recent investigations have discovered a link between the use of gadolinium based contrast agents and the development of a rare, debilitating disease called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD). NSF involves the fibrosis or stiffening and swelling of the skin, joints, internal organs, and other body parts. The disease can also cause discolored, irritated patches of skin. There is no known cure for this potentially fatal disease. The development of NSF/NSD is especially common among patients who have suffered previous kidney problems.

There are currently five gadolinium based contrast agents on the market. They are Magnevist (gadopentetate dimeglumine), Omniscan (gadodiamide), OptiMARK (gadoversetamide), MultiHance (gadobenate dimeglumine), and Prohance (gadoteridol). If you or someone you know has developed Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy as a result of being exposed to any of these products, contact The Thompson Law Firm today for a free consultation.